subsidiaries (0.93) 2.83 (3.76) (132.84) 2 Profit attributable to equity holders of the Company for Q1 2018 was Baht 301.72 million, essentially unchanged from the same period of 2017 The Company and its

value is reduced in the same value making the net profit unchanged. Therefore, in order to comply with the Financial Reporting Standard No. 15 (TFRS 15), subject: The revenue from contracts made with

from financing activities was Baht 1,010.50 million mainly from increased short-term debt. As a result, net cash increased by Baht 667.48 million from the beginning balance. Financing In Q1 2019, finance

7,067.78 million mainly from increased short-term debt. As a result, net cash increased by Baht 1,837.96 million from the beginning balance. Financing For the first half of 2019, finance cost amounted to

remained unchanged at 7.88% in 6M 2018, compared to 7.89% in 6M 2017. 2 Other income The Company and its subsidiaries had other income of Baht 782.60 million, increased by Baht 41.25 million or 5.56 % from

which posted 26% growth yoy due to more intensity treatment, epidemics and weather change in the beginning of this year as well as increasing number of beds in service. Cost of Hospital Operations Cost of

/2019 (3.43%). • The selling expenses of Q1/2020 is much lower due to cutting of unnecessary expenses. However, the administration expenses are almost unchanged because of fixed expenses such as salaries

15% and 14% yoy, respectively. In 2Q’18, the company’s gross margin was 28% of revenue in line with previous year. The unchanged gross margin of 2Q’18 was due to high revenue base of 2Q’17 following

ratio of Domestic: Export was 62:38, unchanged from the same period last year. 1,760 1,500 1,000 1,100 1,200 1,300 1,400 1,500 1,600 1,700 1,800 Q3/16 Q3/17 - 2 1 % Y o Y - 1 7 % Y o Y - 2 1 % Y o Y - 1 7

) higher excise tax as well as sugar tax following the Excise Act, B.E. 2560, effective since 16 September 2017; 5) higher R&D expenses which had quite an impact at the beginning of the projects; and 6